Toronto, Ontario – September 24, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has filed a voluntary Annual Information Form (“AIF”) as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions.
Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, “As Theralase executes on its strategic initiatives of launching its next generation therapeutic laser system, the TLC-2000 in 4Q2014 and approval of an Investigational New Drug (“IND”) application for commencement of a Health Canada / FDA Phase I/IIa clinical trial to prove safety and efficacy in Non Muscle Invasive Bladder Cancer (“NMIBC”) in early 2015, Theralase would like to provide all investors the opportunity to invest in the Company and not be limited to accredited investors.”
About Theralase Technologies Inc.
Founded in 1994, Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and now Theralase’s scientists are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to the DNA of cancer cells and then, when activated by light, destroy the cancer cells.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225